Just months after launching a test for guiding immunotherapy, the glycoproteomics firm has switched priorities to a colorectal cancer screening assay.
InterVenn BioSciences Hits Commercial Phase, Launches Test for Immunotherapy Response in Melanoma
At the ASCO meeting this week, the firm will present validation data on the test, which predicts response to immune checkpoint inhibitors in advanced melanoma.
InterVenn Biosciences Using New Funding to Develop Glycoproteomic Immunotherapy Response Assay
The company is building a blood-based glycoproteomic assay intended to help doctors predict which cancer patients will respond to checkpoint inhibitors.